Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on minimally invasive surgical technologies for sacropelvic disorders, including sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, spinopelvic and sacropelvic fixation, and pelvic trauma. This news page aggregates company press releases and market updates related to SIBN stock and SI-BONE’s sacropelvic platform.
Investors following SI-BONE news can expect regular updates on quarterly and annual financial results, preliminary revenue announcements, and changes to financial guidance. Recent communications have highlighted double-digit worldwide and U.S. revenue growth, gross margin performance, adjusted EBITDA trends, and cash and cash equivalents. The company also reports operational metrics such as the number of active U.S. physicians using its technologies and revenue per sales territory.
Beyond earnings, SI-BONE’s news flow includes information on reimbursement developments, such as New Technology Add-on Payments and other payment designations for procedures involving products like iFuse TORQ TNT and iFuse Bedrock Granite. The company also issues 8-K-linked press releases covering leadership and board changes, including retirements, consulting agreements, and commercial leadership transitions.
Another recurring theme in SI-BONE news is participation in healthcare and medtech investor conferences hosted by firms such as Piper Sandler, Morgan Stanley, Canaccord Genuity, Truist Securities, and Goldman Sachs. These events often feature fireside chats or presentations where management discusses sacropelvic technologies, clinical evidence, and financial performance, with webcasts made available through the investors section of SI-BONE’s website.
For anyone tracking SIBN, this page offers a centralized view of SI-BONE’s earnings releases, preliminary updates, conference appearances, and other company announcements related to its sacropelvic surgical technology platform.
SI-BONE, Inc. (Nasdaq: SIBN) will announce its Q2 2020 financial results post-market on August 3, 2020. The management team will host a conference call at 1:30 PM PT, accessible via the company’s website. SI-BONE specializes in minimally invasive surgical solutions for sacropelvic disorders, notably through its iFuse Implant System, which addresses chronic low back pain. Supported by numerous clinical studies, the iFuse Implant is the only SI joint fusion device with established insurance coverage for the procedure. Detailed company and product information can be found on their website.
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company in California, has successfully re-financed its existing $40 million credit facility. The new five-year term loan, secured through Solar Capital Partners, features an interest rate of 9.40% plus the greater of the 1-month LIBOR Rate or 0.33%. This strategic move will enhance SI-BONE's balance sheet and provide improved operating flexibility. The new loan includes a 36-month interest-only period followed by 24 months of amortization. The refinancing indicates the company's strong operational performance and dedicated team.
SI-BONE, Inc. announces that Aetna has established a positive coverage policy for the iFuse Implant System to treat sacroiliac joint dysfunction. Effective May 28, 2020, this policy grants over 22 million Aetna members access to the minimally invasive SI joint fusion when deemed medically necessary. This decision is supported by extensive clinical evidence, including 5-year results from a prospective study. SI-BONE highlights that the iFuse procedure is crucial for patients suffering from SI joint pain, enhancing accessibility and treatment adoption.
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company, will participate in the Bank of America Securities 2020 Health Care Conference on May 13, 2020. The management team will conduct a live Fireside Chat at 8:40 a.m. PT / 11:40 a.m. ET, accessible via the company's website. SI-BONE specializes in minimally invasive surgery for sacroiliac joint disorders with its iFuse Implant System, which has shown significant clinical benefits in treating chronic low back pain. The company emphasizes the importance of their research-backed device in enhancing patient outcomes.
SI-BONE, Inc. (Nasdaq:SIBN) reported Q1 2020 revenue of $16.8 million, marking a 12% increase year-over-year. U.S. revenue reached $15.3 million, a 14% rise, despite lower case volumes in late March due to COVID-19. Gross margin stood at 89%, down from 90% in 2019, while operating expenses rose 20% to $26.8 million. The net loss was $12.8 million, or $0.47 per diluted share, compared to $9.3 million in the same period last year. The company has withdrawn its 2020 guidance due to COVID-19 uncertainties.